Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders

This article was originally published in The Pink Sheet Daily

Executive Summary

The Paris-based start-up has raised €32 million from venture investors to address two orphan eye disorders, taking advantage of new research and manufacturing techniques in gene therapy.


Related Content

U.K. Venture Group Abingworth Attracts $375M For New Bioventures Fund
Financings Of The Fortnight: Do Larger Series A Rounds Mean Less Successful Exits?
CHOP Commits $50 Million To Gene Therapy Spin-Out Spark Therapeutics
Start-Up Quarterly Statistics, Q2 2013
Biopharma Dealmaking Quarterly Statistics, Q2 2013
Financings of the Fortnight: Getting Comfortable In Genes
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Anticoagulant Maker XO1 Takes $11M In Index Ventures’ Largest Series A
Bluebird Bio Raises $60M Series D Round To Treat Rare Diseases
Sanofi Creates Ophtho Division through Earn-Out Acquisition of Fovea


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts